Pargyline pretreatment prevents immunological changes induced by MPTP in mice

Immunopharmacology

Volumn 35, Issue 2, 1996, Pages 149-154

  Bieganowska, Katarzyna ^a   Członkowska, Anna ^a   Korlak, Janina ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; effect on immune response dopamine depletion; immune reactivity

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATECHOLAMINE; DOPAMINE; PARGYLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; IMMUNOREGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; IMMUNITY; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, INBRED C57BL; PARGYLINE; PHAGOCYTOSIS; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030298122     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(96)00140-3     Document Type: Article

References (24)

1. Arai, N., Misugi, K., Goshima, Y. and Misu, Y., 1990. Evaluation of a 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) treated C57 black mouse model for parkinsonism. Brain Res., 515: 57-63.
2. Asanuma, M., Ogawa, N., Sora, Y.H., Pongdhana, K., Haba, K. and Mori, A., 1990. Alterations of somatostatin and its modulation by levodopa in MPTP treated mice. J. Neurol. Sci., 100: 155-160.
3. Basu, S., Dasgupta, P.S. and Chowdhury, J.R., 1995. Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. J. Neuroimmunol., 60: 18.
4. Bieganowska, K., Członkowska, A., Bidzinski, A., Mierzewska, H. and Korlak, J., 1993. Immunological changes in the MPTP-induced Parkinson's disease mouse model. J. Neuroimmunol., 42: 33-38.
5. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M. and Kopin, I.J., 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Nat. Acad. USA, 80: 4546-4550.
6. Cross, R.J., Jackson, J.C., Brooks, W.H., Sparks, D.L. and Markesberry, W.R., 1986. Neuromodulation: impairement of humoral immune responsiveness by 6-hydroxydopamine treatment. Immunology, 57: 145-152.
7. Cross, R.J., Brooks, W.H. and Roszman, T.L., 1987. Modulation of T suppressor cell activity by central nervous system catecholamine depletion. J. Neurosci. Res., 18: 75-81.
8. Cunningham, A.J. and Szenberg, A., 1968. Further improvements in the plaque technique for detecting single antibody forming cells. Immunology, 14: 59.
9. Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V. and Link, H., 1994. Parkinson's diseases and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol. Scand., 90: 160-166.
10. Fiszer, U., Piotrowska, K., Korlak, J. and Członkowska, A., 1991. The immunological status in Parkinson's disease. Med. Lab. Sci., 48: 196-200.
11. Ganong, W.F., Alper, R.H. and Steels, M.K., 1985. In: ed. N. Ben Jonathon, J.M. Bahrs and R.I. Weiner, Catecholamines as Hormones Regulator. Raven Press, New York, 1985 pp. 13-18.
12. Gillis, S., Ferm, M.M., Ou, W. and Smith, K.A.T., 1978. T cell growth factor: parameters of production and quantitative microassay for activity. J. Immunol., 120: 2027-2032.
13. Haskel, Y. and Hanani, M., 1994. Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Digest. Diseas. Sci., 39(11): 2364-7.
14. Heikkila, R.E. and Sonsalla, P.K., 1992. The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int., 20: 299s-303s.
15. Iyengar, S., Kim, H.S. and Wood, P.L., 1987. μ, δ, κ and ∈ opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res., 435: 220-226.
16. Jankovic, B. and Marie, D., 1990. In vivo modulation of the immune system by enkephalins. Int. J. Neurosci., 51: 167-169.
17. Martilla, R.J., Escola, J., Paivrita, M. and Rinne, U.K., 1984. Immune functions in Parkinson's disease. Adv. Neurol., 40: 315-318.
18. Neveu, P.J. and Le Moal, M., 1990. Physiological basis for neuroimmunomodulation. Fundam. Clin. Pharmacol., 4: 281-305.
19. Ohkawara, S., Ueno, K. and Salon, T., 1989. Reduction of the cellular immune response by 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) in C57/B1 mice. Res. Comm, Substances Abuse., 10: 77-80.
20. Parisi, J.E. and Burns, R.S., 1986. The neuropathology of MPTP induced parkinsonism in man and experimental animals. In: ed. S.P. Markey, N. Castagnoli, A.J. Trevor, J. Kopin, A Neurotoxin Producing a Parkinsonian Syndrom. Academic Press, Orlando, 1986, pp. 141-148.
21. Ricaurte, G.A., Irwin, I., Forno, L., Delanney, S., Langston, E. and Langston, J.W., 1987. Aging and 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res., 403: 43-51.
22. Schneider, J.S., Yuwiler, A. and Markham, C.H., 1986. Production of Parkinson-like syndrom in the cat with N-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP): behaviour, histology and biochemistry. Exp. Neurol., 91: 293-307.
23. Stanisz, A.M., Befus. D. and Bienenstock, J., 1986. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Payer's patches, mesentric lymph nodes and spleen, J. Immunol., 136: 152-156.
24. Wilson, S.P., Change, K.J. and Vireros, O.H., 1980. Synthesis of enkephalins by adrenal medullary chromaffin cells: reserpine increases incorporation of radiolabelled amino acids. Proc. Nat. Acad. Sci., 77: 4764-4368.